MedPath

The Effect of Stellate Ganglion Block on Insomnia Patients

Not Applicable
Recruiting
Conditions
Insomnia
Interventions
Procedure: Stellate Ganglion Block
Registration Number
NCT06255730
Lead Sponsor
Zeng Changhao
Brief Summary

A prospective study was conducted on Insomnia Patients. All the patients were provided with Stellate Ganglion Block. The quality of sleep was evaluated to see if Stellate Ganglion Block can improve Insomnia.

Detailed Description

Insomnia is a sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep, despite having adequate opportunity for sleep. It is a common condition that can significantly impact an individual's quality of life and overall well-being.A prospective study was conducted on Insomnia Patients. All the patients were provided with Stellate Ganglion Block. The quality of sleep was evaluated to see if Stellate Ganglion Block can improve Insomnia.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Insomnia patients with the ages over 18.
  • Meeting the diagnostic criteria for chronic insomnia as per the International Classification of Sleep Disorders (ICSD) or the Diagnostic and Statistical Manual of Mental Disorders (DSM).
  • Experiencing insomnia symptoms persistently for at least three months.
  • Not currently using or ceased using medication for insomnia for at least four weeks.
  • Willing to undergo Stellate Ganglion Block treatment and participate in the study.
Exclusion Criteria
  • Patients with severe cardiovascular disease, pulmonary disease, or other serious physical health issues.
  • Pregnant or lactating women.
  • Patients with mental disorders (such as major depression, anxiety disorders, schizophrenia, etc.) or cognitive impairments.
  • Patients with known allergies or contraindications to Stellate Ganglion Block treatment.
  • Patients currently participating in other clinical trials or receiving experimental treatments.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Stellate Ganglion Block GroupStellate Ganglion BlockStellate Ganglion Block Group will be given Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day
Stellate Ganglion Block GroupLidocaine HydrochlorideStellate Ganglion Block Group will be given Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day
Primary Outcome Measures
NameTimeMethod
Pittsburgh Sleep Quality Indexday 1 and day 10

Pittsburgh Sleep Quality Index (PSQI): The PSQI is a widely used scale that assesses sleep quality, including aspects such as sleep latency, sleep duration, sleep efficiency, sleep disturbances, and daytime dysfunction. The total score ranges from 0 to 21, with higher scores indicating worse sleep quality.

Secondary Outcome Measures
NameTimeMethod
Sleep Impairment Indexday 1 and day 10

Sleep Impairment Index (SII): The SII is a scale that measures the impact of sleep disorders on daily functioning. It includes nine items, covering aspects such as feeling unwell in the morning and feeling tired during the day. The total score ranges from 0 to 36, with higher scores indicating more severe sleep impairment.

Anxietyday 1 and day 10

The anxiety was assessed using the Generalized Anxiety Disorder-7, including items related to fear, worry, attention, etc. The total score ranged from 0 to 21, which was positively correlated with potential anxiety. In the previous study, the scale demonstrated a Cronbach's α-coefficient of 0.879.

Trial Locations

Locations (1)

Center Rehabilitation Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath